Paul Tudor Jones's GILD Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 128,173 shares of Gilead Sciences, Inc. (GILD) worth $14.23 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in GILD, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2024, adding 273,136 shares. Largest reduction occurred in Q3 2024, reducing 521,017 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Gilead Sciences (GILD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Gilead Sciences (GILD) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +9,201 | Add 0.00% | 9,200 | $51.30 |
| Q3 2013 | -9,200 | Sold Out | 0 | $0.00 |
| Q4 2013 | +7,997 | New Buy | 7,997 | $75.15 |
| Q1 2014 | +2,808 | Add 35.11% | 10,805 | $70.89 |
| Q2 2014 | -1,501 | Reduce 13.89% | 9,304 | $82.87 |
| Q3 2014 | +20,941 | Add 225.08% | 30,245 | $106.46 |
| Q4 2014 | +79,127 | Add 261.62% | 109,372 | $94.26 |
| Q1 2015 | -102,837 | Reduce 94.02% | 6,535 | $98.09 |
| Q2 2015 | +3,845 | Add 58.84% | 10,380 | $117.05 |
| Q3 2015 | -3,080 | Reduce 29.67% | 7,300 | $98.22 |
| Q4 2015 | +9,314 | Add 127.59% | 16,614 | $101.18 |
| Q1 2016 | +24,735 | Add 148.88% | 41,349 | $91.85 |
| Q2 2016 | -27,598 | Reduce 66.74% | 13,751 | $83.41 |
| Q3 2016 | -10,951 | Reduce 79.64% | 2,800 | $79.29 |
| Q4 2016 | +8,601 | Add 307.18% | 11,401 | $71.57 |
| Q1 2017 | +9,308 | Add 81.64% | 20,709 | $67.94 |
| Q2 2017 | -20,709 | Sold Out | 0 | $0.00 |
| Q4 2017 | +3,947 | New Buy | 3,947 | $71.70 |
| Q1 2018 | +20,144 | Add 510.36% | 24,091 | $75.38 |
| Q2 2018 | +3,764 | Add 15.62% | 27,855 | $70.83 |
| Q3 2018 | -7,581 | Reduce 27.22% | 20,274 | $77.19 |
| Q4 2018 | +35,364 | Add 174.43% | 55,638 | $62.55 |
| Q1 2019 | +65,481 | Add 117.69% | 121,119 | $65.01 |
| Q2 2019 | -45,338 | Reduce 37.43% | 75,781 | $67.56 |
| Q3 2019 | -30,969 | Reduce 40.87% | 44,812 | $63.38 |
| Q4 2019 | +28,123 | Add 62.76% | 72,935 | $64.98 |
| Q1 2020 | -61,957 | Reduce 84.95% | 10,978 | $74.79 |
| Q2 2020 | -10,978 | Sold Out | 0 | $0.00 |
| Q3 2020 | +25,698 | New Buy | 25,698 | $63.20 |
| Q4 2020 | -25,698 | Sold Out | 0 | $0.00 |
| Q1 2021 | +34,755 | New Buy | 34,755 | $64.62 |
| Q2 2021 | -34,755 | Sold Out | 0 | $0.00 |
| Q3 2021 | +5,586 | New Buy | 5,586 | $69.82 |
| Q4 2021 | +77,289 | Add 1383.62% | 82,875 | $72.62 |
| Q1 2022 | +49,642 | Add 59.90% | 132,517 | $59.45 |
| Q2 2022 | -132,517 | Sold Out | 0 | $0.00 |
| Q2 2023 | +3,874 | New Buy | 3,874 | $77.07 |
| Q3 2023 | -3,874 | Sold Out | 0 | $0.00 |
| Q4 2023 | +37,430 | New Buy | 37,430 | $81.01 |
| Q1 2024 | +273,136 | Add 729.72% | 310,566 | $73.25 |
| Q2 2024 | +210,451 | Add 67.76% | 521,017 | $68.61 |
| Q3 2024 | -521,017 | Sold Out | 0 | $0.00 |
| Q4 2024 | +162,373 | New Buy | 162,373 | $92.37 |
| Q1 2025 | -120,644 | Reduce 74.30% | 41,729 | $112.05 |
| Q2 2025 | -23,936 | Reduce 57.36% | 17,793 | $110.87 |
| Q3 2025 | +110,380 | Add 620.36% | 128,173 | $111.00 |
Paul Tudor Jones's Gilead Sciences Investment FAQs
Paul Tudor Jones first purchased Gilead Sciences, Inc. (GILD) in Q2 2013, acquiring 9,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Gilead Sciences, Inc. (GILD) for 46 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Gilead Sciences, Inc. (GILD) was in Q1 2024, adding 310,566 shares worth $22.75 M.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 128,173 shares of Gilead Sciences, Inc. (GILD), valued at approximately $14.23 M.
As of the Q3 2025 filing, Gilead Sciences, Inc. (GILD) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Gilead Sciences, Inc. (GILD) was 521,017 shares, as reported at the end of Q2 2024.